CliffBio
small molecule

XERAVA

ERAVACYCLINE DIHYDROCHLORIDE

Loss of exclusivityOctober 2037latest FDA-listed patent expiry
CompanyTetraphase Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameXERAVA
Active ingredientERAVACYCLINE DIHYDROCHLORIDE
StrengthEQ 50MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusRX

Listed patents

PatentExpiresType
11578044October 2037substance
10961190October 2037substance
8906887August 2032product
8796245August 2029use U-2380

Regulatory exclusivity

CodeExpires
GAINAugust 2028
NCEAugust 2023

More from Tetraphase Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XERAVA patent cliff — loss of exclusivity October 2037 | CliffBio